middle.news
How Clarity’s $203M Raise Fuels Next-Gen Prostate Cancer Breakthroughs
10:32am on Friday 31st of October, 2025 AEDT
•
Healthcare
Read Story
How Clarity’s $203M Raise Fuels Next-Gen Prostate Cancer Breakthroughs
10:32am on Friday 31st of October, 2025 AEDT
Key Points
Completed $203 million placement at premium share price
Co-PSMA Phase II trial met primary endpoint with superior lesion detection
Ongoing Phase III trials AMPLIFY and CLARIFY progressing recruitment
Preclinical data shows SAR-bisFAP’s superior tumour targeting and efficacy
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CU6
OPEN ARTICLE